⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11967315 | 0.73 | PIK3CA (0.30) | — | |
| SCHEMBL11836639 | 0.73 | — | — | |
| SCHEMBL24391110 | 0.71 | ADA (0.37) | — | |
| SCHEMBL12410702 | 0.70 | PIK3CA (0.39) | — | |
| SCHEMBL18018738 | 0.70 | DGAT1 (0.33) | — | |
| SCHEMBL19121964 | 0.70 | — | — | |
| SCHEMBL17768671 | 0.70 | PIK3CD (0.32) | — | |
| SCHEMBL15357762 | 0.69 | — | — | |
| SCHEMBL15357775 | 0.69 | — | — | |
| Lithium Ion SCHEMBL25376591 | 0.69 | DGAT1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230355599-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2023205180-A1 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230212186-A1 | CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20220289730-A1 | (R)-3-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| US-20220135542-A1 | 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES | PHARVARIS GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| US-20210087529-A1 | CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPY | NURIX THERAPEUTICS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210085717-A1 | CBL INHIBITORS AND COMPOSITIONS FOR EXPANSION OF IMMUNE CELLS | NURIX THERAPEUTICS, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2021021761-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20210017158-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | ANALYTICON DISCOVERY GMBH (DE) | 2021-01-21 | — | — | US | disclosed |
| WO-2020264398-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-10836748-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2020-11-17 | — | — | US | disclosed |
| US-20200323904-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. | 2020-10-15 | — | — | US | disclosed |
| WO-2020210508-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200255405-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | ANALYTICON DISCOVERY GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |